OR WAIT null SECS
Organizations can now confidently leverage social media and messaging platforms to market and share content, writes Dawn Lacallade.
Patients regularly use social media. In some cases, patients seek input and answers from social media before they visit their doctor. A recent survey of doctors by Cello Health Insights revealed 69 per cent of their patients look up their condition online prior to a consultation. While, 62 per cent of patients arrive to the doctors with a diagnosis they researched online. The research revealed that 40 per cent of patients ask for a named drug after having diagnosed themselves online.
Whereas, research findings among the public portray a similar viewpoint:
Despite these behaviors and preferences, many pharmaceutical companies have been hesitant to establish a social media presence, ultimately because social media presents challenges for the pharmaceutical industry due to FDA regulations for adverse events.
There are several reasons that make the case why medicine brands should take part in social media with patients and offer brand channels online. Pharmaceutical companies need to be proactive at managing consumer perception and the reputation of their brand. By monitoring their own social media and online communities, companies are less apt to be caught off guard by negative social comments or adverse events.
This monitoring can even be used in new channels like messaging and chatbots. For example, when a chatbot or other automation receives a user response that mentions key words that alert the brand, those words can trigger a message to a human agent at the brand or partner to review the content and submit it as an adverse event to colleagues in MedReg or pharmacovigilance.
It’s important that the technology and adverse events reporting tools brands utilize for adverse event management in social media and messaging maintain the company’s compliance with the FDA, can escalate chatbot adverse event conversations to humans, continually monitor and act when adverse events occur, as well as report and archive conversations for regulatory compliance.
Using FDA compliance software tools and human interaction that ensure compliance, pharma companies have much more they can gain by developing marketing, social and messaging campaigns. After all, Facebook’s Messenger platform has more than 1.3 billion monthly active users. Facebook-owned messaging apps send billions of messages a day. If you’re wondering how these chatbots and Messenger could help your brand derive value from social media, here are a few use cases to advance communications utilizing these channels:
Many healthcare companies are using social media, in-app messaging, and chatbot experiences to work for them in a variety of ways, and with great success. With that in mind, here are a few examples of how these channels could empower brands to improve processes, engagement, and better meet the expectations of patients:
Messenger enables pharmaceutical companies to have conversations and share information with consumers worldwide. One of the most well-known chatbot examples and human interaction, is HealthTap. HealthTap is an interactive health company that has developed a Messenger chatbot, which allows patients to quickly find out what they may be suffering from and how to talk about their possible condition with their healthcare provider.
If the answer isn’t part of the chatbot’s scripted response, a patient can submit questions to more than 100,000 doctors in the U.S. The patient can expect an answer within 24 hours or request a live consultation. By partnering with Facebook Messenger, HealthTap immediately increased their reach to more than 1.3 billion users that already have Messenger installed on their devices.
Using Messenger’s social media presence, there are innumerable ways that pharmaceutical brands could use chatbots in the messaging platform to streamline business operations, while enhancing the patient experience.
Although pharma brands are highly regulated, chatbots and Messenger can help marketers accomplish their business objectives in new ways. Chatbots may never be able to replace human interaction, but they can help pharma marketers scale ordinary regular tasks.
Organizations can now confidently leverage social media and messaging platforms to market and share content such as disease-specific educational information for consumers, the latest details on new drugs, devices, or to create patient support groups and online communities. With modern FDA adverse events monitoring software and human agents, these channels can help marketers identify the unmet needs of patients, innovate, and figure out where marketing dollars should be spent to have the greatest impact and satisfy patient needs and demands.